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INTRODUCTION
Anorectal malignant melanoma (AMM), which has rare 
incidence, is as less than 0.05%–4.6% of anorectal malignancies 
[1,2]. Every year, 76,000 people are newly diagnosed with 
melanoma in America, and among them 6,100 are diagnosed 
as mucosal melanoma, which is 0.38% of newly diagnosed 
cancer patients in America [3]. In Europe, 47,241 people are 
newly diagnosed with malignant melanoma of the skin, and 
its incidence rate is 11.4% [4]. Seventy-nine AMM cases were 
reported for 10 years in Japan, and they showed very poor 
survival [5]. AMM has a very poor prognosis, with a 5-year 
survival rate between 6%–22% [6-9]. The management of AMM 
is challenging. Due to its low incidence, AMM has not been 
studied well, and most of the publications are case reports or 
series. Although various treatment modalities for AMM have 
been suggested including surgical resection, chemotherapy, 
and radiotherapy, all of them are debatable and evidence 
is insufficient. Moreover, a randomized controlled trial is 
impossible in AMM due to its rarity. 
When we review the articles concerning about AMM, the 
physiologic and medical features of AMM are described in 
similar detail in most articles. Although every article agrees 
that the initial treatment of AMM should be surgical resection, 
the method of surgical resection has many debates among the 
many authors. In Korea, there have been several case reports 
and review articles of AMM, though the ideal option for surgical 
excision is not concluded [10]. This review aimed to review 
the management of AMM in current studies in order to better 
understand AMM.
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Anorectal malignant melanoma (AMM) is a very rare and aggressive disease. The purpose of this article is to review 
the clinical features of AMM, to understand treatment options, and optimal therapy by reviewing pertinent literature. 
Traditionally an abdominoperineal resection (APR) sacrificing the anal sphincter has been performed for radical resection 
of cancer, but recently, wide excision of AMM is attempted since quality of life after surgery is an important issue. Some 
authors reported that there was no difference in five-year survival between the patient who underwent an APR and wide 
excision. The goal of both APR and wide excision was to improve survival with R0 resection. Adjuvant chemoradiation 
therapy can be performed to achieve an R0 resection. AMM shows very poor prognosis. At this time, research on AMM 
is insufficient to suggest a treatment guideline. Thus, treatment options, and a therapeutic method should be selected 
carefully.
[Ann Surg Treat Res 2014;87(3):113-117]
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INCIDENCE AND CLINICAL MANIFESTATIONS
AMM is a very rare disease and accounts for less than 0.05%–
4.6% of all anorectal malignancies [1,2]. AMM is the third most 
common primary origin of melanoma following skin and retina 
[2]. Malignant melanoma arising in anorectal lesions accounts 
for 0.4%–1.6% of all malignant melanomas [11]. AMM patients 
are more frequently female [6,11,12,14,15], and the median age 
at diagnosis is 60 years or higher [6,11,12]. 
The main complaint of an AMM patient is not specific com-
pared with other anorectal benign or malignant dise ase. The 
most frequent symptom of AMM patient is blee ding (54%–78%) 
[6,7,11]. Other symptoms include mass (12%–16%) [6,7,11], pain 
(14%–27%) [6,7,11], obstipation (6%) [11], diarrhea (4%) [11], and 
pathologic diagnosis after a hemorrhoidectomy (8%–16%) [7,11]. 
Moreover, AMM is sometimes diagnosed by a routine health 
check-up without any symptoms [16]. In the literature review, 
more than 50% of patients complained of rectal bleeding. Due 
to delayed diagnosis and the aggressive nature of AMM, 37% 
of the patients already had distant or regional metastasis at 
the time of diagnosis [17]. Weinstock [14] reported that at the 
time of diagnosis only 37% of AMM is confined at the anorectal 
area, 41% has regional spread and 22% has distant metastasis. 
Lymphatic spread is common and tends to involve mesenteric 
and inguinal lymph nodes [18]. The major sites of distant 
metastasis are lung, liver, and bone [18]. The brain is the most 
common metastasis site, followed by liver and lung [19].
SURGICAL TREATMENT
The treatment of AMM has not been standardized due to 
low incidence and lack of evidence. For now, treatment results 
are evaluated by survival rates alone [20]. There are various 
treatment modalities of AMM, including surgical excision, 
chemotherapy, radiation therapy, and immunotherapy. 
However, there is no definite treatment of choice.
Generally, surgical excision is considered a primary treatment 
option for AMM. Traditionally, APR is regarded as the standard 
surgery for AMM [7,21,22]. APR is preferred because it can 
control lymphatic spread (mainly to mesenteric lymph nodes) 
and guarantee a larger negative margin for local control [23]. 
Ishizone et al. [2] reported that APR with lymph node dissec-
tion should be performed because of regional lymph node 
metastasis if there is submucosal invasiong (T1). However, due 
to high morbidity and mortality of APR, Wide local excision 
(WLE) is also advocated by some authors [12,20,23,24]. WLE 
has many benefits such as quicker recovery, minimal impact 
on bowel function and no need for a stoma [18]. Some reports 
suggest that APR leads to complications such as urinary and 
sexual dysfunction and has no advantage over WLE [18,25]. 
However, Ramalingam et al. [13] documented that laparoscopic 
APR could control disease and reduce morbidity at the same 
time. Between the two groups who underwent APR and WLE, 
there was no difference in five year survival rates [7-9,25-27].
Bullard et al. [25] reported that APR has no benefit for locore-
gional recurrence and systemic recurrence compared to WLE. 
This means that most recurrences occur systemically regardless 
of the initial surgical procedure [18]. Locoregional recurrence 
of AMM occurs more at the inguinal lymph nodes than at 
the pelvic lymph nodes [9]. Neither APR nor WLE affect any 
of the inguinal lymph nodes, therefore neither of them offers 
an advantage in controlling locoregional recurrence [9,28]. 
However, it is important to achieve a negative resection margin 
irrespective of the surgical method performed for local control 
[28]. WLE with successful R0 resection could show better 
survival than APR [28]. WLE is curative for stage 0 disease and 
would be proper concerning the quality of life. 
The depth and size of tumor is one of the important prog-
nostic factors. If the lesion is thick (>3 mm) and large (>30 
mm), curative surgery cannot be achieved [29]. In this case, 
conservative local excision and adjuvant therapy can result in a 
better prognosis [6]. At the time of diagnosis, if AMM is already 
in the advanced stage, surgical options should be selected based 
on quality of life [30]. For advanced stage, WLE with adjuvant 
radiotherapy and biochemotherapy could be done concerning 
favorable functional outcome and longer median survival. 
Conclusively, most authors suggest that WLE should be the 
first treatment of choice if surgically feasible, and APR would be 
the palliative method when there is obstruction and need for 
salvage surgery [19,24,31].
RADIOTHERAPY
Adjuvant radiation therapy after surgical excision has also 
been attempted. Radiotherapy to extended field followed 
by sphincter saving wide excision reduced locoregional 
recurrence rate to 17% from 50% compared to WLE alone [32]. In 
comparison to APR, WLE with adjuvant radiotherapy achieves 
equal locoregional control [33]. In fact, extended radiation 
therapy to the pelvic/inguinal lymph nodes is associated with 
serious complications such as lymphedema and proctitis 
[32,34]. Preoperative neoadjuvant radiotherapy demonstrated 
only minimal effect on local tumor burden [34]. Adjuvant 
radiotherapy can decrease locoregional recurrence, but distant 
relapse, which cannot be controlled, is the main cause of death 
[32]. Gupta et al. [35] investigated interstitial brachytherapy 
with caesium-137 and analyzed its ability to prevent local 
recurrence.
CHEMOTHERAPY
Currently, a standard therapeutic regimen for chemotherapy 
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in the setting of AMM does not exist. In addition, the rarity 
of AMM makes it difficult to evaluate the clinical efficacy of 
systemic therapy [36]. Many regimens, including dacarbazine, 
Bacile Calmette-Gurin (BCG), levamisole, cisplatin, vinblastine, 
intereukin-2 and interferon, have been investigated [16,25]. These 
regimens are based on drugs developed for advanced cutaneous 
melanoma [16].
OTHER TREATMENTS
Recently, the use of immune-modulating agent for cancer 
treatment has increased, since chemotherapy or radiotherapy 
alone is insufficient to completely eradicate AMM. Moreover, 
immunotherapy can boost anticancer immunity [37]. Immuno-
chemotherapy is a chemotherapy regimen which includes an 
immunologic agent. Immunochemotherapy includes specific 
active immunization and adoptive immunotherapy based on 
antigenic system [38]. The response rate of dacarbazine, which 
is one of the most effective agents for metastatic melanoma, 
is only 20% [23,39]. Immunochemotherapy use with cisplatin, 
vinblastine, dacarbazine, interferon alpha-2b and interleukin-2 
demonstrated similar overall response and complete response 
rates to that of advanced cutaneous melanoma [36]. Phade and 
Lawrence [40] reported a case review of immunochemotherapy 
(dacarbazine, BCG) with encouraging results. When comparing 
patients treated with and without biochemotherapy, the former 
group showed a longer median survival [36].
A newly developed agent, temozolomide, demonstrates 
equi vocal efficacy to dacarbazine and is an oral alternative 
for advanced metastatic melanoma [41]. Yeh et al. [42] admi-
nistered a combination of temozolomide, cisplatin and lipo-
somal doxorubicin (intrahepatic infusion to liver me ta stasis) 
in a patient whose primary lesion was unre sectable, and 
regression of the primary and metastatic tumors was con-
firmed.
PROGNOSIS
The prognosis of AMM is very poor due to its aggressive 
characteristics. The five year survival rate of AMM is 6%–22% 
[6-9], and the median survival in the literature is 19–26.4 
months [6,7,26]. The five year survival rate varies according to 
the presence of metastasis. If AMM is confined to the local 
area, the five year survival rate is 37%–50% [14,17]. However, if 
there is regional and distant metastasis, the five year survival 
rate decreases in 7%–17% and 0%–6%, respectively [14,17]. 
Though the prevalence of AMM in women is higher, the overall 
survival was longer in women compared to men (15.7% and 
10.6%, respectively) [28].
The prognosis of AMM differs depending on the stage of 
AMM. There is no specific system for staging of AMM at this 
point. Ross et al. [9] classified AMM patients into three stages; 
stage I (localized disease), stage II (regional disease), and stage 
III (with distant metastasis). According to this staging system, 
stage I was associated with better survival results than stage 
II or III [26]. Concerning cutaneous melanoma, (1) thickness of 
cancer, (2) mitotic rate, and (3) presence of ulceration are the 
most important prognostic factors [43]. The thickness of the 
tumor proves to be an influential factor in AMM, and thickness 
less than 2 mm is the major factor for determining long-term 
survival [6,8,23,44]. In AMM, ulceration is frequently seen 
on examination of the gross specimen of AMM [36]. It has 
been proven by various institutions that the tumor depth has 
a significant effect on the survival rate [23,45,46]. The size of 
the tumor can also determine the survival [7]. In addition, the 
nodal status at the time of diagnosis is another predictive factor 
[23]. At the time of diagnosis, a patient with nodal metastasis 
had decreased five year disease-specific survival, disease-free 
survival and distant metastasis-free survival compared to those 
patients without nodal metastasis [33]. Duration of the initial 
symptom also influences the prognosis [23]. As the initial 
symptom is similar to that of hemorrhoids, clinicians often 
look over it as a common benign disease. Therefore diagnosis of 
AMM is frequently delayed [36].
The relationship between the tumor location and prognosis 
is unclear at this point. If the tumor locates proximal to the 
dentate line, the disease showed an advanced stage more than 
the distal tumor. If the tumor is located proximal to the dentate 
line, the disease stage is more advanced than if the tumor 
is located distal to the dentate line. However, if the tumor is 
located distal to the dentate line, the lymph node recurrence 
rate is higher than if the tumor is proximal to the dentate line. 
Therefore, the overall prognosis of the two groups is not signi fi-
cantly different [47].
As mentioned before, nodal metastasis can be a prognostic 
factor of AMM. If R0 resection is not successful and metastatic 
lymph nodes remain, regional recurrence is more likely [28]. 
However, prophylactic lymph node dissection for every patient 
is too risky due to the complexity of the procedure [18]. Sentinal 
lymph node mapping (SLNM) is used in cutaneous melanoma 
to determine the extent of excision. SLNM could potentially be 
used in AMM. In the circumstance of pathologically positive 
nodal metastasis but clinically negative nodal metastasis, SLNM 
can prevent understaging [18]. SLNM can also aid in planning 
the extent of surgery [48].
CONCLUSION
AMM has no treatment guidelines currently, the choice 
of therapeutic method should be carefully considered. Early 
diagnosis and a tailored, multidisciplinary treatment plan 
would likely improve the treatment result of AMM. Large scale 
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prospective clinical trials should be conducted in the future to 
investigate effective treatments for AMM.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
1. Falch C, Stojadinovic A, Hann-von-
Weyhern C, Protic M, Nissan A, Faries MB, 
et al. Anorectal malignant melanoma: 
extensive 45-year review and proposal for 
a novel staging classification. J Am Coll 
Surg 2013;217:324-35.
2. Ishizone S, Koide N, Karasawa F, Akita 
N, Muranaka F, Uhara H, et al. Surgical 
treatment for anorectal malignant mela-
noma: report of five cases and review 
of 79 Japanese cases. Int J Colorectal Dis 
2008;23:1257-62.
3. Siegel R, Ward E, Brawley O, Jemal A. 
Cancer statistics, 2011: the impact of 
elimi nating socioeconomic and racial 
disparities on premature cancer deaths. 
CA Cancer J Clin 2011;61:212-36.
4. International Ageny for Research on 
Cancer. Malignant melanoma of skin 
[Internet]. Lyon: International Ageny for 
Research on Cancer; c2012 [cited 2014 
Mar 14]. Available from: http://eu-cancer.
iarc.fr/EUCAN/Cancer.aspx?Cancer=20.
5. National Cancer Center, Center for Can cer 
Control and Information Services. Can-
cer Statistics in Japan [Internet]. Tokyo: 
National Cancer Center, Center for Can-
cer Control and Information Services; 
[cited 2014 Mar 14]. Available from: 
http://ganjoho.jp/pro/statistics/en/table_
download.html.
6. Wanebo HJ, Woodruff JM, Farr GH, Quan 
SH. Anorectal melanoma. Cancer 1981; 
47:1891-900.
7. Brady MS, Kavolius JP, Quan SH. Anorectal 
melanoma. A 64-year experience at Me-
morial Sloan-Kettering Cancer Center. Dis 
Colon Rectum 1995;38:146-51.
8. Thibault C, Sagar P, Nivatvongs S, Ilstrup 
DM, Wolff BG. Anorectal melanoma--
an incurable disease? Dis Colon Rectum 
1997;40:661-8.
9. Ross M, Pezzi C, Pezzi T, Meurer D, Hickey 
R, Balch C. Patterns of failure in anorectal 
melanoma. A guide to surgical therapy. 
Arch Surg 1990;125:313-6.
10. Ma MS, Kim CY, Kim JA. Anorectal 
malignant melanoma: a case report. J 
Korean Surg Soc 1997;52:458-64.
11. Goldman S, Glimelius B, Pahlman L. Ano-
rectal malignant melanoma in Sweden. 
Report of 49 patients. Dis Colon Rectum 
1990;33:874-7.
12. Cagir B, Whiteford MH, Topham A, Ra-
kinic J, Fry RD. Changing epidemiology of 
anorectal melanoma. Dis Colon Rectum 
1999;42:1203-8.
13. Ramalingam G, Gan EY, Kutt-Sing W. La-
pa ro scopic abdominoperineal resection for 
anorectal melanoma: a case report and 
re view of the literature. Surg Laparosc En-
dosc Percutan Tech 2009;19:e149-51.
14. Weinstock MA. Epidemiology and prog-
nosis of anorectal melanoma. Gastro ente-
ro logy 1993;104:174-8.
15. Heeney A, Mulsow J, Hyland JM. Treat-
ment and outcomes of anorectal mela-
noma. Surgeon 2011;9:27-32.
16. Homsi J, Garrett C. Melanoma of the anal 
canal: a case series. Dis Colon Rectum 
2007;50:1004-10.
17. Podnos YD, Tsai NC, Smith D, Ellenhorn 
JD. Factors affecting survival in patients 
with anal melanoma. Am Surg 2006; 
72:917-20.
18. Stoidis CN, Spyropoulos BG, Misiakos 
EP, Fountzilas CK, Paraskeva PP, Fotiadis 
CI. Diffuse anorectal melanoma; review 
of the current diagnostic and treatment 
aspects based on a case report. World J 
Surg Oncol 2009;7:64.
19. Aytac B, Adim SB, Yerci O, Yilmazlar T. 
Anorectal malignant melanomas: expe-
rience of Uludag University. Kaohsiung J 
Med Sci 2010;26:658-62.
20. Yap LB, Neary P. A comparison of wide 
local excision with abdominoperineal 
resection in anorectal melanoma. Mela-
noma Res 2004;14:147-50.
21. Cooper PH, Mills SE, Allen MS Jr. Malig-
nant melanoma of the anus: report of 12 
patients and analysis of 255 additional 
cases. Dis Colon Rectum 1982;25:693-703.
22. Chiu YS, Unni KK, Beart RW Jr. Malignant 
melanoma of the anorectum. Dis Colon 
Rectum 1980;23:122-4.
23. Pessaux P, Pocard M, Elias D, Duvillard 
P, Avril MF, Zimmerman P, et al. Surgical 
management of primary anorectal mela-
noma. Br J Surg 2004;91:1183-7.
24. Yeh JJ, Shia J, Hwu WJ, Busam KJ, Paty 
PB, Guillem JG, et al. The role of abdo-
minoperineal resection as surgical the-
rapy for anorectal melanoma. Ann Surg 
2006;244:1012-7.
25. Bullard KM, Tuttle TM, Rothenberger DA, 
Madoff RD, Baxter NN, Finne CO, et al. 
Surgical therapy for anorectal melanoma. 
J Am Coll Surg 2003;196:206-11.
26. Slingluff CL Jr, Seigler HF. Anorectal 
melanoma: clinical characteristics and 
the role of abdominoperineal resection. 
Ann Plast Surg 1992;28:85-8.
27. Ward MW, Romano G, Nicholls RJ. The 
surgical treatment of anorectal malignant 
melanoma. Br J Surg 1986;73:68-9.
28. Nilsson PJ, Ragnarsson-Olding BK. Impor-
tance of clear resection margins in ano-
rec tal malignant melanoma. Br J Surg 
2010;97:98-103.
29. Fukui R, Hata F, Yasoshima T, Honma 
T, Nomura H, Sasaki K, et al. Malignant 
melanoma of the anorectum: report of 
REFERENCES
 Annals of Surgical Treatment and Research 117
four cases. Surg Today 2002;32:555-8.
30. Carcoforo P, Raiji MT, Palini GM, Pedriali 
M, Maestroni U, Soliani G, et al. Primary 
anorectal melanoma: an update. J Cancer 
2012;3:449-53.
31. Seol BR, Bae HD, Lee CW. Anal malignant 
melanoma: a case report and review of 
literatures. J Korean Surg Soc 1993;44:306-
14.
32. Kelly P, Zagars GK, Cormier JN, Ross MI, 
Guadagnolo BA. Sphincter-sparing local 
excision and hypofractionated radiation 
therapy for anorectal melanoma: a 20-
year experience. Cancer 2011;117:4747-55.
33. Ballo MT, Gershenwald JE, Zagars GK, 
Lee JE, Mansfield PF, Strom EA, et al. 
Sphincter-sparing local excision and adju-
vant radiation for anal-rectal mela noma. J 
Clin Oncol 2002;20:4555-8.
34. Moozar KL, Wong CS, Couture J. Anorectal 
malignant melanoma: treatment with 
surgery or radiation therapy, or both. Can 
J Surg 2003;46:345-9.
35. Gupta R, Sharma SC, Bose SM. Adjuvant 
interstitial brachytherapy in a case of 
anorectal melanoma. Trop Gastroenterol 
2000;21:86-7.
36. Kim KB, Sanguino AM, Hodges C, Papado-
poulos NE, Eton O, Camacho LH, et al. 
Biochemotherapy in patients with meta-
static anorectal mucosal melanoma. Can-
cer 2004;100:1478-83.
37. Vacchelli E, Prada N, Kepp O, Galluzzi L. 
Current trends of anticancer immuno-
che motherapy. Oncoimmunology 2013;2: 
e25396.
38. Kim JO, Yang HY, Son S, Park KH. Clinical 
experiences in malignant melanoma. J 
Korean Surg Soc 1997;53:905-10.
39. Hill GJ 2nd, Krementz ET, Hill HZ. Dime-
thyl triazeno imidazole carboxamide and 
combination therapy for melanoma. IV. 
Late results after complete response to 
chemotherapy (Central Oncology Group 
protocols 7130, 7131, and 7131A). Cancer 
1984;53:1299-305.
40. Phade VR, Lawrence WR. Anorectal mela-
noma. Br J Surg 1981;68:667-8.
41. Middleton MR, Grob JJ, Aaronson N, 
Fierlbeck G, Tilgen W, Seiter S, et al. 
Randomized phase III study of temozo-
lomide versus dacarbazine in the treat-
ment of patients with advanced meta-
static malignant melanoma. J Clin Oncol 
2000;18:158-66.
42. Yeh JJ, Weiser MR, Shia J, Hwu WJ. Res-
ponse of stage IV anal mucosal melanoma 
to chemotherapy. Lancet Oncol 2005;6: 
438-9.
43. Balch CM, Gershenwald JE, Soong SJ, 
Thompson JF, Atkins MB, Byrd DR, et al. 
Final version of 2009 AJCC melanoma 
staging and classification. J Clin Oncol 
2009;27:6199-206.
44. Soong SJ, Ding S, Coit D, Balch CM, Ger-
shenwald JE, Thompson JF, et al. Pre-
dicting survival outcome of localized 
me lanoma: an electronic prediction tool 
based on the AJCC Melanoma Database. 
Ann Surg Oncol 2010;17:2006-14.
45. Che X, Zhao DB, Wu YK, Wang CF, Cai JQ, 
Shao YF, et al. Anorectal malignant mela-
nomas: retrospective experience with 
surgical management. World J Gastro-
enterol 2011;17:534-9.
46. Siegal B, Cohen D, Jacob ET. Surgical 
treatment of anorectal melanomas. Am J 
Surg 1983;146:336-8.
47. Bello DM, Smyth E, Perez D, Khan S, 
Temple LK, Ariyan CE, et al. Anal versus 
rectal melanoma: does site of origin 
predict outcome? Dis Colon Rectum 2013; 
56:150-7.
48. Olsha O, Mintz A, Gimon Z, Gold Deutch 
R, Rabin I, Halevy A, et al. Anal melanoma 
in the era of sentinel lymph node map-
ping: a diagnostic and therapeutic chal-
lenge. Tech Coloproctol 2005;9:60-2.
Soomin Nam, et al: Anorectal malignant melanoma
